Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm

Bassand, J.-P. · 2007 · European Heart Journal

Abstract

Over the last two decades, major improvements in clinical outcome have been achieved in the management of acute coronary syndromes (ACS), with or without ST-segment elevation. In both these clinical settings, the pharmacological approach comprising anti-platelet agents, (or a combination thereof), anticoagulants, thrombolytic treatment in case of ST-elevation MI (STEMI) combined with mechanical or surgical revascularization or reperfusion, has led to a dramatic reduction in the rate of ischaemic events, namely death, death/myocardial infarction (MI), or death/MI/stroke. However, this has been achieved at the cost of a higher risk of bleeding complications, which were considered, until recently, to be inherent to ACS management, and to be a side effect devoid of serious clinical implications, except for intra-cranial bleeding. Bleeding complications were thought to be the price to pay for the improvement in the risk of ischaemic events, and were considered to be easily controlled, particularly thanks to a liberal transfusion policy. In this context, the risk factors for bleeding have been identified, and include baseline characteristics, such as age, female gender, renal failure, diabetes, and heart failure. In addition, the number and dosage of anti-thrombotic drugs, the use of fibrinolytic treatments, and the use of invasive strategies, required to achieve mechanical reperfusion or revascularization, also play an important role.1,2 However, over the last 5 years, it has become clear that bleeding complications occurring during the initial phase of ACS have a considerable impact on prognosis, especially in terms of death, MI, and stroke, both in the short- and long-term. A four- to five-fold increase in the risk of death, MI, and stroke at 30 days has been observed in patients with bleeding events, as compared to those without.2–4 The potential mechanisms by which bleeding leads to a deterioration of prognosis are multiple, and include haemodynamic compromise, hyperadrenergic state triggered by blood loss and blood pressure drop, worsening of myocardial ischaemia, exaggeration of the inflammatory response, and also discontinuation of anti-thrombotics. In addition, transfusion may also add to the risk. A three- to four-fold increase in the risk of death at 30 days was observed in patients who were transfused, as compared to those who were not, in a meta-analysis of several trials in the setting of ACS.5 Depletion of 2,3-diphosphoglycerate and nitric oxide in stored blood cells leading to reduced oxygen delivery at tissue level, an exaggeration of myocardial ischaemia, and generalized vasoconstriction are thought to be the main factors explaining the potential deleterious effects of transfusion on outcome.6,7 Lastly, anaemia at baseline has also been shown to be a predictor of the risk of ischaemic events, with a ‘J-shaped’ relation between baseline haemoglobin levels and the rate of ischaemic events. Higher rates of ischaemic events have been observed with both high and low baseline haemoglobin levels, with the lowest rate of events being observed for haemoglobin levels in the range of 14–16 g/dL.8 Decreased oxygen supplies to the myocardium, compounded by increased myocardial oxygen demand because of the higher cardiac output required to maintain adequate systemic oxygenation, are the potential mechanisms by which anaemia exerts its deleterious effects. Inadequate remodelling may also play a role in the risk. Interestingly, data from a large trial in the setting of NSTE-ACS showed that the risk reduction for bleeding at 9 days had a huge impact on the risk of death, death/MI, and death/MI/stroke, shown to be significantly reduced at 30 days and 6 months.9 In this trial, almost the entire reduction in the risk of death was explained by the risk reduction for bleeding. In other words, the loop is closed—an excess of bleeding leads to an excess of ischaemic events, but a reduction in bleeding complications leads to a risk reduction for ischaemic events. A new concept is therefore born—bleeding carries a high risk of death and MI, and transfusion could be potentially deleterious. Prevention of bleeding has the potential to reduce the risk of death, MI, and stroke, and has become as equally as important as the prevention of ischaemic events. In this regard, the paper by Aronson et al.10 sheds further light on this issue. This is a prospective study assessing the impact of admission, nadir, and discharge haemoglobin levels during hospital stay, on the in-hospital, and long-term outcome in terms of ischaemic events and occurrence of congestive heart failure. In this paper, anaemia at admission, according to the WHO definition, was observed in only 17.8% of patients. Major and minor bleedings occurred in 3.7 and 9.7%, respectively. However, more than 50% of patients experienced a drop in haemoglobin of >1.3 g/dL during hospitalization, which means that many of them may have had occult bleeding, or oozing, not serio

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehm132

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 364

Metadata

Authors
Bassand, J.-P.
Venue
European Heart Journal
Published
2007-06-01
Volume
28
Issue
11
Pages
1273-1274
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2162064711
Cited by
364
References
10
FWCI
31.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. https://app.cochat.ai/papers/10.1093/eurheartj/ehm132
The paper
Bassand, J.-P. (2007). Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. European Heart Journal. https://doi.org/10.1093/eurheartj/ehm132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.